Review kidney transplant graft-survival context from donor age, HLA mismatch, cold ischemia time, PRA, donor type, and retransplant status in a simplified educational worksheet.
Kidney transplant outcomes vary with donor quality, immunologic compatibility, ischemia time, sensitization burden, and recipient factors. HLA mismatch, PRA, donor type, donor age, and cold ischemia time are all familiar parts of that discussion, but real transplant decisions also depend on crossmatch results, donor-specific antibodies, KDPI, biopsy findings, and center-specific practice.
This page combines those visible factors into a simplified graft-survival worksheet. It summarizes the major donor-quality and immunologic features that are commonly discussed before transplantation, but it does not reproduce any official allocation score or transplant-center workflow.
The output should be read as broad prognosis context only. It is useful for education and discussion framing, not for organ acceptance, desensitization planning, or immunosuppression decisions.
Transplant recipients and teams need a simple way to summarize how donor age, HLA mismatch, PRA, and ischemia time move the overall risk picture. This page is most useful when it supports counseling and prognosis discussion without pretending to replace the center’s actual matching workflow.
Site-defined graft-survival worksheet: - donor type, donor age, HLA-A/B/DR mismatch, cold ischemia time, PRA, sensitization history, DCD status, and retransplant history each contribute weighted points - higher points move the case into broader risk bands with lower worksheet graft-survival context - this is an educational summary model, not an allocation or crossmatch algorithm
Result: Standard worksheet band, 1-year graft context ~94%, 5-year ~82%, 10-year ~65%
A 52-year-old recipient receiving a kidney from a 38-year-old deceased donor with 1 HLA-A mismatch, PRA 25%, and 14 hours cold ischemia falls into the worksheet’s standard band. These are broad context estimates only, not center-specific predictions.
This page keeps the main donor-quality and immunologic variables together: donor age, donor type, HLA mismatch, cold ischemia time, PRA, sensitization history, and retransplant status. That makes it useful for educational review when discussing why one transplant scenario looks lower or higher risk than another.
Actual transplant decisions depend on more than the factors shown here. Crossmatch results, donor-specific antibodies, KDPI, biopsy findings, infection history, and the transplant center’s own practice all matter, and they may outweigh the worksheet score.
Use the output as broad counseling context only. It is most helpful as a way to summarize donor-quality and immunologic factors before the real transplant review, not as a substitute for the center’s matching and immunosuppression process.
Last updated:
This page is a site-defined graft-survival worksheet that combines donor type, donor age, HLA-A/B/DR mismatch, cold ischemia time, PRA, sensitization history, DCD status, and retransplant status into broad risk bands. It is meant to summarize the main donor-quality and immunologic factors people commonly discuss before kidney transplantation.
It is not a transplant-allocation model and it does not represent a center’s crossmatch or immunosuppression workflow. Donor-specific antibodies, virtual or flow crossmatch results, KDPI, biopsy findings, and center-specific acceptance criteria remain more important than the worksheet alone.
HLA-DR antigens are expressed on antigen-presenting cells and directly activate CD4+ T helper cells, which orchestrate the adaptive immune response against the graft. DR mismatches generate the strongest immune response and have the most significant impact on both acute rejection episodes and long-term graft survival. A single DR mismatch is roughly equivalent to two HLA-A or HLA-B mismatches in terms of immunologic risk.
Cold ischemia time (CIT) is the duration from when the donor organ is flushed with preservation solution and cooled until blood flow is restored in the recipient. During this period, ischemia-reperfusion injury occurs. CIT > 24 hours significantly increases delayed graft function (DGF) risk, which in turn increases acute rejection and chronic graft loss. Living donor kidneys have minimal CIT (usually < 2 hours), contributing to their superior outcomes.
PRA measures the percentage of a panel of donor lymphocytes that react with the recipient's serum. A PRA of 50% means the recipient has antibodies against 50% of potential donors. High PRA results from prior sensitization events: blood transfusions, pregnancies, or prior transplants. Highly sensitized patients (PRA > 80%) qualify for priority allocation under UNOS but still face higher rejection risk even with a crossmatch-negative donor.
Living donor kidneys have 3-5 year longer graft half-lives compared to deceased donor kidneys. This is due to several factors: minimal cold ischemia time (usually < 2 hours versus 12-24+ hours), ability to thoroughly evaluate donor health, scheduling the transplant when the recipient is optimally prepared, and typically younger/healthier donor demographics. The 10-year graft survival for living donor kidneys approaches 80% versus 55-65% for deceased donors.
DBD (donation after brain death) is the traditional deceased donor pathway where brain death is declared before organ procurement. DCD (donation after circulatory death) involves organ procurement after withdrawal of life-sustaining treatment and circulatory arrest. DCD kidneys experience a period of warm ischemia before procurement, which increases delayed graft function risk. However, long-term outcomes of DCD kidneys are approaching those of DBD kidneys in experienced centers.
Absolutely. Even highly sensitized patients (PRA > 80%) derive survival benefit from transplantation versus remaining on dialysis. Modern desensitization protocols (plasmapheresis, IVIg, rituximab, bortezomib) can make transplantation possible across positive crossmatches. Paired kidney exchange programs and the UNOS priority allocation for sensitized patients have shortened waitlist times. Virtual crossmatch technology has improved pre-transplant antibody assessment.